The present study, the FXLEARN trial (ClinicalTrials.gov NCT02920892; Figure 1), was designed to address the methodological concerns of prior studies and provide an answer to the question of efficacy of mGluR5 NAMs in FXS. The gene discussed is GRM5; the disease is fragile X syndrome.